SCHEMBL20242568

SCHEMBL20242568

CC1(C)OC(=O)C(C)(CC2CC2)C(=O)O1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.33
POLB P06746 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TP53 P04637 3/20 0.32
CYP3A4 P08684 3/20 0.32
MAPK1 P28482 3/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
HIF1A Q16665 2/20 0.32
LMNA P02545 2/20 0.32
CYP1A2 P05177 2/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
NFKB1 P19838 1/20 0.32
THPO P40225 1/20 0.32
PPM1B O75688 1/20 0.32
PTPN1 P18031 1/20 0.32
PPP1CC P36873 1/20 0.32
TFPI2 P48307 1/20 0.32
PPP5C P53041 1/20 0.32
PPP2CA P67775 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16174694 0.70 PTPN1 (0.33) TSHRLMNAPTPN1KDM4E
SCHEMBL3091285 0.67 GLA (0.41) MAPT
SCHEMBL21961915 0.65 CTSD (0.32) TSHRLMNA
SCHEMBL13758455 0.65
SCHEMBL3715467 0.64 ALDH1A1 (0.36) TSHRL3MBTL1SMN1; SMN2LMNACYP1A2
SCHEMBL12669329 0.64
SCHEMBL1562353 0.63 TSHR (0.38) TSHRPOLBL3MBTL1SMN1; SMN2LMNA
SCHEMBL892475 0.62 TSHR (0.39) TSHRPOLBL3MBTL1TP53CYP3A4
SCHEMBL16768500 0.62 TSHR (0.35) TSHRPOLBL3MBTL1TP53CYP3A4
SCHEMBL15960847 0.62 TSHR (0.36) TSHRPOLBL3MBTL1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12180211-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2024-12-31 US disclosed
EP-3552017-B1 COMPOUNDS USEFUL AS RIPK1 INHIBITORS DENALI THERAPEUTICS INC (US) 2022-02-23 EP disclosed
US-20210332058-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2021-10-28 US disclosed
US-11072618-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2021-07-27 US disclosed
EP-3552017-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2019-10-16 EP disclosed
US-20190300537-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2019-10-03 US disclosed
WO-2018107060-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2018-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12180211-B2 Compounds, compositions and methods BAX, CASP3, CASP8 TSHR 4796/4885POLB 918/4885L3MBTL1 657/4885
US-11072618-B2 Compounds, compositions and methods BAX, CASP3, CASP8 TSHR 4796/4885POLB 918/4885L3MBTL1 657/4885
US-20210332058-A1 Compounds, Compositions and Methods BAX, CASP3, CASP8 TSHR 4796/4885POLB 918/4885L3MBTL1 657/4885
US-20190300537-A1 Compounds, Compositions and Methods BAX, CASP3, CASP8 TSHR 4796/4885POLB 918/4885L3MBTL1 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.